|
Synonyms: TACI-Fc | TACI-Ig
Compound class:
Peptide or derivative
Comment: Atacicept is a recombinant fusion protein that was designed to inhibit B cells, and which was investigated as an intervention in autoimmune diseases [2]. Mechanistically atacicept neutralises the function of two important B-cell activating factors, BAFF (BLyS) and APRIL. Structurally atacicept contains the BLyS/APRIL-binding extracellular portion of the TACI receptor fused to a modified Fc from human IgG1 [4]. One of the important functions of these two factors in autoimmune disease is their ability to induce proliferation of plasma cells and thus increase Ig production, in particular the production of destructive anti-self antibodies. However, this modality has proven ineffective in autoimmune diseases in clinical studies. As of June 2021 atacicept was being deployed for IgA nephropathy.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for atacicept is claimed in patent WO2002094852 [8]. |
| No information available. |
Summary of Clinical Use  |
| Atacicept was investigated for clinical efficacy in a range of autoimmune conditions e.g. SLE [3], rheumatoid arthritis [10] and optic neuritis (a demyelinating inflammation of the optic nerve) [9]. These trials have largely been unsuccessful., however Vera Therapeutics believe it may have potential for IgA nephropathy (based on results from Merck's trial NCT02808429 in patients with kidney disease IgA nephropathy), and as of January 2021 they were planning on taking atacicept forward for this indication. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00642902 | A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) | Phase 2 Interventional | EMD Serono | 1,5 | |
| NCT02808429 | Efficacy and Safety of Atacicept in IgA Nephropathy | Phase 2 Interventional | EMD Serono | ||
| NCT01972568 | Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus | Phase 2 Interventional | EMD Serono | 6-7 | |
| NCT00624338 | Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) | Phase 2/Phase 3 Interventional | EMD Serono | 4 | |
| NCT04716231 | Atacicept in Subjects With IgA Nephropathy | Phase 2 Interventional | Vera Therapeutics, Inc. | ||
